Your browser doesn't support javascript.
loading
Medical devices used in NICU: The main source of plasticisers' exposure of newborns.
Bernard, Lise; Masse, Morgane; Boeuf, Benoît; Chennell, Philip; Decaudin, Bertrand; Durand, Nelly; Genay, Stéphanie; Lambert, Céline; Le Basle, Yoann; Moreau, Emmanuel; Pinguet, Jérémy; Ponsonnaille, Varlane; Richard, Damien; Saturnin, Nathalie; Storme, Laurent; Sautou, Valérie.
Afiliação
  • Bernard L; Université Clermont Auvergne, Clermont Auvergne INP, CNRS, CHU Clermont Ferrand, ICCF, F-63000 Clermont-Ferrand, France. Electronic address: l_bernard@chu-clermontferrand.fr.
  • Masse M; Univ. Lille, CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
  • Boeuf B; CHU Clermont-Ferrand, Service Réanimation pédiatrique et médecine néonatale, Clermont-Ferrand, France.
  • Chennell P; Université Clermont Auvergne, Clermont Auvergne INP, CNRS, CHU Clermont Ferrand, ICCF, F-63000 Clermont-Ferrand, France.
  • Decaudin B; Univ. Lille, CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
  • Durand N; CIC 1405, Unité CRECHE, INSERM, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France.
  • Genay S; Univ. Lille, CHU Lille, ULR 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000 Lille, France.
  • Lambert C; CHU Clermont-Ferrand, Direction de la Recherche Clinique et Innovation, Clermont-Ferrand, France.
  • Le Basle Y; Université Clermont Auvergne, Clermont Auvergne INP, CNRS, CHU Clermont Ferrand, ICCF, F-63000 Clermont-Ferrand, France.
  • Moreau E; Université Clermont-Auvergne, INSERM U1240 Imagerie Moléculaire et Stratégies Théranostiques, F-63000 Clermont Ferrand, France.
  • Pinguet J; CHU Clermont-Ferrand, Université Clermont-Auvergne, service de Pharmacologie médicale, UMR INSERM 1107 Neuro-Dol, F-63000 Clermont-Ferrand, France.
  • Ponsonnaille V; CHU Clermont-Ferrand, Service Réanimation pédiatrique et médecine néonatale, Clermont-Ferrand, France.
  • Richard D; CHU Clermont-Ferrand, Université Clermont-Auvergne, service de Pharmacologie médicale, UMR INSERM 1107 Neuro-Dol, F-63000 Clermont-Ferrand, France.
  • Saturnin N; CHU Clermont-Ferrand, Service Réanimation pédiatrique et médecine néonatale, Clermont-Ferrand, France.
  • Storme L; CHRU Lille, Service de Médecine Néonatale, F-59000 Lille, France; Université Lille I, UPRES EA 4489, Laboratoire de Périnatalité et croissance, F-59000 Lille, France.
  • Sautou V; Université Clermont Auvergne, Clermont Auvergne INP, CNRS, CHU Clermont Ferrand, ICCF, F-63000 Clermont-Ferrand, France.
Sci Total Environ ; 858(Pt 3): 159994, 2023 Feb 01.
Article em En | MEDLINE | ID: mdl-36368381
Phthalates and other plasticisers are extensively used in medical devices (MD) from which they can leach out and lead to potential multiple problems for the patients. This exposure is a major issue because it is associated with reproductive and neurodevelopment disorders. The Neonatal Intensive Care Units (NICU) population is at high risk due to the daily intensive medical interventions, the reduced ability of newborns to remove these contaminants and their higher sensitivity to endocrine disruptors. We conducted a multicentric biomonitoring study to assess and compare the urinary levels of DEHP (di-(2-ethylhexyl)phthalate), DEHTP (di-(2-ethylhexyl)terephthalate) and TEHTM (tri-(2-ethylhexyl)trimellitate) metabolites as biomarkers of this exposure during and after the newborns' stay in NICU. Daily urinary samples were collected in NICU and at discharge from the hospital for each patient. MD sources and exposure factors were also investigated. 508 urinary samples from 97 patients enrolled in centres 1 and 2 (C1/C2) were collected. The exposure of newborns to DEHP was greater than that of DEHTP and TEHTM, with a median concentration of DEHP metabolites (C1:195.63 ng/mL;C2:450.87 ng/mL) respectively 5 to 10 times higher and 57 to 228 times higher than the median concentrations of DEHTP and TEHTM metabolites. The urinary concentrations of DEHP and TEHTM metabolites were significantly lower at discharge than in NICU, with a 18-and 35-fold decrease for DEHP and a 4 and 8-fold decrease for TEHTM, respectively for C1 and C2, but were similar for DEHTP metabolites. MD used for respiratory assistance, infusion therapy,enteral nutrition and transfusion were the main sources of exposure. Smaller gestational age and body weight significantly increased the newborns' exposure. The elevated levels of DEHP metabolites in NICU patients are still alarming. Additional efforts are necessary to promote its substitution in MD by possibly safer alternatives such as TEHTM and DEHTP, particularly when used for the care of newborns.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Ftálicos / Plastificantes / Unidades de Terapia Intensiva Neonatal / Disruptores Endócrinos Tipo de estudo: Clinical_trials Limite: Humans / Newborn Idioma: En Revista: Sci Total Environ Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos Ftálicos / Plastificantes / Unidades de Terapia Intensiva Neonatal / Disruptores Endócrinos Tipo de estudo: Clinical_trials Limite: Humans / Newborn Idioma: En Revista: Sci Total Environ Ano de publicação: 2023 Tipo de documento: Article